- Exchange: ASE
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Snapshot for CSL Ltd (CSL)
| Open: | 61.3000 | Day's Range: | 60.5300 - 61.6100 | Volume: | 1,942,839 |
|---|---|---|---|---|---|
| Previous Close: | 60.8500 | 52wk Range: | 36.5500 - 64.7000 | 1-Yr Rtn: | +66.30% |
Key Statistics for CSL
| Current P/E Ratio (ttm) | 26.4630 |
|---|---|
| Estimated P/E(06/2013) | 24.7114 |
| Relative P/E vs. AS51 | 1.2586 |
| Earnings Per Share (USD) (ttm) | 2.2495 |
| Est. EPS (USD) (06/2013) | 2.4090 |
| Est. PEG Ratio | 1.7740 |
| Market Cap (M AUD) | 30,092.17 |
| Shares Outstanding (M) | 493.72 |
| 30 Day Average Volume | 1,231,412 |
| Price/Book (mrq) | 8.4672 |
| Price/Sale (ttm) | 6.3655 |
| Dividend Indicated Gross Yield | 1.57% |
| Cash Dividend (AUD) | 0.4866 |
| Last Dividend | 03/05/2013 |
| 5 Year Dividend Growth | 18.27% |
| Next Earnings Announcement | 08/14/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for CSL
Company Profile & Key Executives for CSL
CSL Limited develops, manufactures and markets human pharmaceutical and diagnostic products derived from human plasma. The Company's products include pediatric and adult vaccines, infection and pain medicine, skin disorder remedies, antivenoms, anticoagulants and immunoglobulins.
| John ShineChairman | Brian A McNameeCEO/Managing Director |
| Paul PerreaultCEO/Managing Director | Gordon NaylorChief Financial Officer |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
CSL News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page